Outsourcing

Sep 01, 2005
BioPharm International
In addition to India and China, other Asian countries are establishing themselves as destinations for biopharma companies.
Jun 01, 2005
BioPharm International
By BioPharm International Editors
Less than 35 percent of all biotech companies have sufficient finances to survive beyond one year.
Jun 01, 2005
BioPharm International
Avariety of forces are combining to fundamentally change the financial dynamics of the biopharmaceutical industry. The initial public offering (IPO) appears to be giving way to licensing arrangements with, and acquisitions by, major pharmaceutical companies.
May 01, 2005
BioPharm International
By BioPharm International Editors
Your company's job is to make biopharmaceutical products. Managing facilities is a function supporting the main task. General manufacturing companies discovered this long ago, but pharmaceutical producers have been lagging. Once you consider the outsouring of non-core activities like facility management (FM), office services, space planning, and utilities management, you can focus on core business functions that make profits.
Apr 01, 2005
BioPharm International
Contract manufacturers must plan for increased analytical resources in development and quality control.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Outsourcing is becoming increasingly widespread and essential in the biopharmaceutical industry. Its imprint on biotech world business and on the development of biopharmaceutical drugs is becoming ever more pronounced. It is estimated that almost one-half of biopharmaceutical companies contract out at least part of the production of their products. On the other hand, those companies that do not outsource production often contract out some of their development activities.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Mass serialization, or the ability to store a unique serial number for each item, is the most useful feature of RFID tags.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
During the past several years in the pharmaceutical and biopharmaceutical industries, conflicts and misunderstandings have arisen between companies and their contractors. Too often, productive working relationships have crumbled, resulting in expensive production delays with companies and contractors squabbling over their roles and responsibilities. Such conflicts may have their roots in the lack of a sound quality agreement (QAG). QAGs that clearly delineate good manufacturing practice (GMP) responsibilities between a sponsor and a contractor can help companies and their contractors avoid certain conflicts.
Feb 01, 2005
BioPharm International
By BioPharm International Editors
The bulk of a biopharmaceutical processing unit can be assembled with off-the-shelf components. However, special fabrications — especially fluid components — enable fabricators and manufacturers to meet critical construction deadlines and move projects forward with minimal or no delays.
Feb 01, 2005
BioPharm International
By BioPharm International Editors
Speed of response, small-scale manufacturing and process flexibility will become increasingly important.
native1_300x100
lorem ipsum